Therefore, this study incorporates findings from twelve trials to comprehensively evaluate the effectiveness and safety of integrating poly ADP-ribose polymerase (PARP) inhibitors into the therapy for advanced lung cancer. The gene discussed is PARP1; the disease is lung carcinoma.